Literature DB >> 19066907

[Risk factors and prevention of retinopathy of prematurity].

L Pelken1, R F Maier.   

Abstract

The history of retinopathy of prematurity (ROP) gives a prime example of how dangerous the uncontrolled introduction of a new medical treatment--particularly in the field of neonatology--may be. The most important risk factors for the development of ROP are the immaturity of premature infants as well as uncontrolled and/or inadequate treatment with oxygen. In comparison to the fetus, the premature infant is exposed to a nonphysiologically high oxygen concentration. This hyperoxia leads to formation of aggressive oxygen radicals on the one hand and, on the other hand, to temporarily reduced production of growth factors such as vascular endothelial growth factor and erythropoietin, which both play an important role in the pathogenesis of ROP. The most important measure to prevent ROP is restrictive and carefully monitored oxygen treatment. Medical treatment to prevent ROP includes injection of D-penicillamine and retinol, but the available data are still limited, particularly with regard to the long-term effects of this treatment. A higher oxygenation in prethreshold ROP does not lead to recovery of ocular findings, but it increases the incidence of pulmonary complications. A reduction of light intensity in neonatal intensive care units proved not to be efficient for preventing ROP. To avoid blindness, standardized screening of the risk group is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19066907     DOI: 10.1007/s00347-008-1788-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  69 in total

1.  Intraventricular haemorrhage and stage 3 retinopathy of prematurity.

Authors:  P Watts; G G Adams; R M Thomas; C Bunce
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Fibroblastic Overgrowth of Persistent Tunica Vasculosa Lentis in Infants Born Prematurely: II. Report of Cases-Clinical Aspects.

Authors:  T L Terry
Journal:  Trans Am Ophthalmol Soc       Date:  1942

3.  Does observer bias contribute to variations in the rate of retinopathy of prematurity between centres?

Authors:  Brian A Darlow; Mark J Elder; L John Horwood; Deborah A Donoghue; David J Henderson-Smart
Journal:  Clin Exp Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 4.207

4.  Incidence, progression, and duration of retinopathy of prematurity in Hispanic and white non-Hispanic infants.

Authors:  Kyle J Eliason; J Dane Osborn; Eric Amsel; Scott C Richards
Journal:  J AAPOS       Date:  2007-05-10       Impact factor: 1.220

5.  Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (</=1000 g) neonates?

Authors:  M G Karlowicz; P J Giannone; J Pestian; A L Morrow; J Shults
Journal:  Pediatrics       Date:  2000-05       Impact factor: 7.124

Review 6.  Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

Authors:  A Ohlsson; S M Aher
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

7.  Childhood blindness.

Authors:  P G Steinkuller; L Du; C Gilbert; A Foster; M L Collins; D K Coats
Journal:  J AAPOS       Date:  1999-02       Impact factor: 1.220

8.  Screening guidelines for retinopathy of prematurity: the need for revision in extremely low birth weight infants.

Authors:  M Subhani; A Combs; P Weber; C Gerontis; J D DeCristofaro
Journal:  Pediatrics       Date:  2001-04       Impact factor: 7.124

9.  Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study.

Authors:  Tatiana Smolkin; Maya Steinberg; Polo Sujov; Eedy Mezer; Ada Tamir; Imad R Makhoul
Journal:  Acta Paediatr       Date:  2008-03       Impact factor: 2.299

10.  Endothelial nitric oxide synthase gene T-786C and 27-bp repeat gene polymorphisms in retinopathy of prematurity.

Authors:  Krisztina Rusai; Adám Vannay; Beáta Szebeni; Gábor Borgulya; Andrea Fekete; Barna Vásárhelyi; Tivadar Tulassay; Attila J Szabó
Journal:  Mol Vis       Date:  2008-02-05       Impact factor: 2.367

View more
  4 in total

1.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

2.  [Pathogenesis of retinopathy of prematurity].

Authors:  A Stahl; W A Lagrèze; H T Agostini
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

Review 3.  Screening and Treatment in Retinopathy of Prematurity.

Authors:  Andreas Stahl; Wolfgang Göpel
Journal:  Dtsch Arztebl Int       Date:  2015-10-23       Impact factor: 5.594

4.  Clinical Efficacy of Topical CoQ10 and Vitamin-E Eye-drop in Retinopathy of Prematurity.

Authors:  Muberra Akdogan; Onur Polat
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2019-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.